Completed PHASE2 NCT00122434

Dose Finding Study in COPD

A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Sponsor: Boehringer Ingelheim

Conditions Pulmonary Disease, Chronic Obstructive

Interventions BEA 2180 BR tiotropium

Updated 7 times since 2017 Last updated: Dec 27, 2017 Started: Jul 31, 2005 Primary completion: May 31, 2006

A PHASE2 clinical study on Pulmonary Disease, Chronic Obstructive, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 7 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jan 2018 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Jan 2018 [monthly]

Completed PHASE2

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Almelo, Netherlands , Angleur, Belgium , Bay Pines, United States , Birmingham, United States , Breda, Netherlands , Brussels, Belgium , Charleston, United States , Coeur d'Alene, United States , Edegem, Belgium , Fredericksburg, United States and 31 more locations